Conference Day Two
Thursday 14th September 2023
7:30 am
Morning Registration & Networking
8:20 am Chairperson’s Opening Remarks
Analysing Boundaries Between Cosmetics & Therapeutics: A Holistic Approach
8:30 am A Year in Review: Exploring the Current Challenges & Opportunities in Skin Microbiome Research & Product Development
Synopsis
- Outlining novel understandings of the skin microbiome
- Revealing product development updates
- Exploring future potential for product development targeting the skin microbiome
9:00 am Micrococcus luteus BLIS Q24™ – Development of a Novel Skin Probiotic Strain & Formulation
Synopsis
- Characterising a new probiotic strain for skin health applications
- Formulating BLIS Q24™ into an appropriate topical delivery system
- The emerging evidence base supporting BLIS Q24™
9:10 am Translating Ancestral Skin Microbiome Research into Synergistic Skincare Products
Synopsis
- Exploring the ways our modern lifestyle influences the skin’s microbiome
- Uncovering an evolutionary biology perspective of the skin microbiome
- Translating ancestral microbiome research into skincare products
9:40 am Developing Personalized Microbiome-Targeting Skincare Solutions
Synopsis
- Exploring how skin microbiome testing informs personalization at Parallel
- Outlining Phages and their role in personalized skincare
- Looking at the future of personalization based on data, ML, and AI
10:10 am
Morning Break & Networking
Advancing Skin Microbiome Tools & Technologies to Expand Our Understanding on the Effect of Microbiome-Targeting Products
10:45 am Discovery of an S. aureus-pacifying Microbial Ensemble via Massively Parallel Measurement of 6 Million Microbial Interactions
Synopsis
- With its groundbreaking discovery platform, kChip, which produces and measures half a million defined microbial combinations each day, Concerto identifies microbes most likely to work together as disease treatments
- Using kChip to measure >6 million combinations of skin microbes and discover a beneficial microbial community, “Ensemble No.2”
- We subsequently showed that Ensemble No.2 suppresses S. aureus growth and virulence on a preclinical skin model. We’re now developing Ensemble No.2 as a topical treatment for S. aureus-driven conditions such as atopic dermatitis
11:15 am Utilizing Microbiome Engineering Tools to Treat Skin Diseases
Synopsis
- Outlining how genetic and microbial engineering are key to enhancing microbial function on the skin
- Using such tool to enhance safety, efficacy, or functionality in designing live biotherapeutic products
- Outlining these tools in the context of skin diseases
11:45 am Roundtables: Advancing Cosmetic & Therapeutic Development Through Novel Research Methodologies & Techniques
Synopsis
- Discussing what is holding the skin microbiome industry back, from sample collection to formulation and delivery
- Uncovering what technological investments need to be made by the industry to propel the field fowards
12:15 pm
Lunch Break & Networking
Navigating the Evolving Regulatory & Investment Landscape
1:15 pm Outlining Cosmetic & Therapeutic Patent IP Strategy
Synopsis
- Developing life cycle management strategy for key company innovations
- Obtaining issued composition of matter IP quickly and in a cost effective matter
- Implementing an effective Freedom to Operate strategy to support business decision making, investments, and collaborations
1:45 pm Navigating Cosmetic Claims Substantiation: A Case Study
Synopsis
- Uncovering some of the challenges incurred during the claims process at Cybele Microbiome
- Exploring the steps the field need to take to streamline the process
- Encouraging greater industry credibility through a thorough substantiation process
2:15 pm Panel Discussion: Attracting More Investment for Microbiome-Based Skin Solutions
Synopsis
- Analysing investment trends, therapeutic vs cosmetic
- Reviewing the current therapeutic landscape
- Exploring the start-up landscape